首页 > 最新文献

ACS Medicinal Chemistry Letters最新文献

英文 中文
Novel 1,6-Naphthridine Compounds as SMARCA2 Inhibitors for Treating Non-small Cell Lung Cancer.
IF 3.5 3区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2025-02-14 eCollection Date: 2025-03-13 DOI: 10.1021/acsmedchemlett.5c00048
Ram W Sabnis

Provided herein are novel 1,6-naphthridine compounds as SMARCA2 inhibitors, pharmaceutical compositions, use of such compounds in treating non-small cell lung cancer and processes for preparing such compounds.

{"title":"Novel 1,6-Naphthridine Compounds as SMARCA2 Inhibitors for Treating Non-small Cell Lung Cancer.","authors":"Ram W Sabnis","doi":"10.1021/acsmedchemlett.5c00048","DOIUrl":"10.1021/acsmedchemlett.5c00048","url":null,"abstract":"<p><p>Provided herein are novel 1,6-naphthridine compounds as SMARCA2 inhibitors, pharmaceutical compositions, use of such compounds in treating non-small cell lung cancer and processes for preparing such compounds.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 3","pages":"371-372"},"PeriodicalIF":3.5,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912262/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143655532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In This Issue, Volume 16, Issue 2
IF 3.5 3区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2025-02-13 DOI: 10.1021/acsmedchemlett.5c0002710.1021/acsmedchemlett.5c00027
John G. Woodland, 
{"title":"In This Issue, Volume 16, Issue 2","authors":"John G. Woodland,&nbsp;","doi":"10.1021/acsmedchemlett.5c0002710.1021/acsmedchemlett.5c00027","DOIUrl":"https://doi.org/10.1021/acsmedchemlett.5c00027https://doi.org/10.1021/acsmedchemlett.5c00027","url":null,"abstract":"","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 2","pages":"176–177 176–177"},"PeriodicalIF":3.5,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143397266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Discovery of HMPL-306 (Ranosidenib), a New Potent and Selective Dual Inhibitor of Mutant IDH1 and 2 in Clinical Development for Cancer Treatment.
IF 3.5 3区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2025-02-13 eCollection Date: 2025-03-13 DOI: 10.1021/acsmedchemlett.4c00625
Kun Xiao, Zheng Zhang, Yao Wu, Gang Li, Jia Chen, Yongxin Ren, Na Yang, Jinghong Zhou, Wei Zhang, Jian Wang, Zeyu Zhong, Sumei Xia, Guanglin Wang, Na Li, Wenji Li, Ling Feng, Weihan Zhang, Weiguo Su, Guangxiu Dai

Mutations in isocitrate dehydrogenase (IDH) 1 or 2 are identified in various cancers. Accumulated (R)-2-hydroxyglutarate (2-HG) caused by mutant IDHs leads to blockage of cell differentiation, thereby inducing malignant transformation. Herein we describe the medicinal chemistry efforts that discovered novel mutant IDH inhibitor HMPL-306 (ranosidenib) via structure-activity relationship studies and pharmacokinetic optimization from internal hit compound 1. HMPL-306 is a potent and selective dual inhibitor of mutant IDH1 and 2. It demonstrated favorable preclinical pharmacokinetics and safety profiles, reduced 2-HG in vivo robustly and sustainably in the mutant IDH1 and 2 tumor xenograft models, and displayed high brain penetration in mice. In the clinical studies, the drug showed good safety and encouraging efficacy in patients with relapsed/refractory myeloid malignancies carrying IDH1 and/or IDH2 mutations.

{"title":"Discovery of HMPL-306 (Ranosidenib), a New Potent and Selective Dual Inhibitor of Mutant IDH1 and 2 in Clinical Development for Cancer Treatment.","authors":"Kun Xiao, Zheng Zhang, Yao Wu, Gang Li, Jia Chen, Yongxin Ren, Na Yang, Jinghong Zhou, Wei Zhang, Jian Wang, Zeyu Zhong, Sumei Xia, Guanglin Wang, Na Li, Wenji Li, Ling Feng, Weihan Zhang, Weiguo Su, Guangxiu Dai","doi":"10.1021/acsmedchemlett.4c00625","DOIUrl":"10.1021/acsmedchemlett.4c00625","url":null,"abstract":"<p><p>Mutations in isocitrate dehydrogenase (IDH) 1 or 2 are identified in various cancers. Accumulated (<i>R</i>)-2-hydroxyglutarate (2-HG) caused by mutant IDHs leads to blockage of cell differentiation, thereby inducing malignant transformation. Herein we describe the medicinal chemistry efforts that discovered novel mutant IDH inhibitor HMPL-306 (ranosidenib) via structure-activity relationship studies and pharmacokinetic optimization from internal hit compound <b>1</b>. HMPL-306 is a potent and selective dual inhibitor of mutant IDH1 and 2. It demonstrated favorable preclinical pharmacokinetics and safety profiles, reduced 2-HG <i>in vivo</i> robustly and sustainably in the mutant IDH1 and 2 tumor xenograft models, and displayed high brain penetration in mice. In the clinical studies, the drug showed good safety and encouraging efficacy in patients with relapsed/refractory myeloid malignancies carrying IDH1 and/or IDH2 mutations.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 3","pages":"454-463"},"PeriodicalIF":3.5,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912272/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143655512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Discovery of HMPL-306 (Ranosidenib), a New Potent and Selective Dual Inhibitor of Mutant IDH1 and 2 in Clinical Development for Cancer Treatment
IF 3.5 3区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2025-02-13 DOI: 10.1021/acsmedchemlett.4c0062510.1021/acsmedchemlett.4c00625
Kun Xiao, Zheng Zhang, Yao Wu, Gang Li, Jia Chen, Yongxin Ren, Na Yang, Jinghong Zhou, Wei Zhang, Jian Wang, Zeyu Zhong, Sumei Xia, Guanglin Wang, Na Li, Wenji Li, Ling Feng, Weihan Zhang, Weiguo Su and Guangxiu Dai*, 

Mutations in isocitrate dehydrogenase (IDH) 1 or 2 are identified in various cancers. Accumulated (R)-2-hydroxyglutarate (2-HG) caused by mutant IDHs leads to blockage of cell differentiation, thereby inducing malignant transformation. Herein we describe the medicinal chemistry efforts that discovered novel mutant IDH inhibitor HMPL-306 (ranosidenib) via structure–activity relationship studies and pharmacokinetic optimization from internal hit compound 1. HMPL-306 is a potent and selective dual inhibitor of mutant IDH1 and 2. It demonstrated favorable preclinical pharmacokinetics and safety profiles, reduced 2-HG in vivo robustly and sustainably in the mutant IDH1 and 2 tumor xenograft models, and displayed high brain penetration in mice. In the clinical studies, the drug showed good safety and encouraging efficacy in patients with relapsed/refractory myeloid malignancies carrying IDH1 and/or IDH2 mutations.

{"title":"Discovery of HMPL-306 (Ranosidenib), a New Potent and Selective Dual Inhibitor of Mutant IDH1 and 2 in Clinical Development for Cancer Treatment","authors":"Kun Xiao,&nbsp;Zheng Zhang,&nbsp;Yao Wu,&nbsp;Gang Li,&nbsp;Jia Chen,&nbsp;Yongxin Ren,&nbsp;Na Yang,&nbsp;Jinghong Zhou,&nbsp;Wei Zhang,&nbsp;Jian Wang,&nbsp;Zeyu Zhong,&nbsp;Sumei Xia,&nbsp;Guanglin Wang,&nbsp;Na Li,&nbsp;Wenji Li,&nbsp;Ling Feng,&nbsp;Weihan Zhang,&nbsp;Weiguo Su and Guangxiu Dai*,&nbsp;","doi":"10.1021/acsmedchemlett.4c0062510.1021/acsmedchemlett.4c00625","DOIUrl":"https://doi.org/10.1021/acsmedchemlett.4c00625https://doi.org/10.1021/acsmedchemlett.4c00625","url":null,"abstract":"<p >Mutations in isocitrate dehydrogenase (IDH) 1 or 2 are identified in various cancers. Accumulated (<i>R</i>)-2-hydroxyglutarate (2-HG) caused by mutant IDHs leads to blockage of cell differentiation, thereby inducing malignant transformation. Herein we describe the medicinal chemistry efforts that discovered novel mutant IDH inhibitor HMPL-306 (ranosidenib) via structure–activity relationship studies and pharmacokinetic optimization from internal hit compound <b>1</b>. HMPL-306 is a potent and selective dual inhibitor of mutant IDH1 and 2. It demonstrated favorable preclinical pharmacokinetics and safety profiles, reduced 2-HG <i>in vivo</i> robustly and sustainably in the mutant IDH1 and 2 tumor xenograft models, and displayed high brain penetration in mice. In the clinical studies, the drug showed good safety and encouraging efficacy in patients with relapsed/refractory myeloid malignancies carrying IDH1 and/or IDH2 mutations.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 3","pages":"454–463 454–463"},"PeriodicalIF":3.5,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143600174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel Tryptamine Compounds as 5-HT2A Agonists for Treating Mood Disorders such as Depressive Disorders and Bipolar Disorders.
IF 3.5 3区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2025-02-13 eCollection Date: 2025-03-13 DOI: 10.1021/acsmedchemlett.5c00047
Ram W Sabnis, Anika R Sabnis

Provided herein are novel tryptamine compounds as 5-HT2A agonists, pharmaceutical compositions, use of such compounds in treating mood disorders such as depressive disorders and bipolar disorders and processes for preparing such compounds.

{"title":"Novel Tryptamine Compounds as 5-HT2A Agonists for Treating Mood Disorders such as Depressive Disorders and Bipolar Disorders.","authors":"Ram W Sabnis, Anika R Sabnis","doi":"10.1021/acsmedchemlett.5c00047","DOIUrl":"10.1021/acsmedchemlett.5c00047","url":null,"abstract":"<p><p>Provided herein are novel tryptamine compounds as 5-HT2A agonists, pharmaceutical compositions, use of such compounds in treating mood disorders such as depressive disorders and bipolar disorders and processes for preparing such compounds.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 3","pages":"373-374"},"PeriodicalIF":3.5,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912261/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143655553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of Indazole- and Azaindazole-Substituted Cyclopentapyrroles as G2019S Leucine-Rich Repeat Kinase 2 Inhibitors for the Treatment of CNS Disorders
IF 3.5 3区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2025-02-13 DOI: 10.1021/acsmedchemlett.5c0004510.1021/acsmedchemlett.5c00045
Siyan Feng,  and , Steven H. Liang*, 

This patent describes a novel class of novel indazole/azaindazole-substituted cyclopentapyrroles, which selectively inhibit the Leucine-Rich Repeat Kinase 2 (LRRK2) with G2019S mutation. These LRRK2 inhibitors are proposed for treating Parkinson’s diseases, Alzheimer’s disease, and other central nervous system (CNS) disorders.

{"title":"Identification of Indazole- and Azaindazole-Substituted Cyclopentapyrroles as G2019S Leucine-Rich Repeat Kinase 2 Inhibitors for the Treatment of CNS Disorders","authors":"Siyan Feng,&nbsp; and ,&nbsp;Steven H. Liang*,&nbsp;","doi":"10.1021/acsmedchemlett.5c0004510.1021/acsmedchemlett.5c00045","DOIUrl":"https://doi.org/10.1021/acsmedchemlett.5c00045https://doi.org/10.1021/acsmedchemlett.5c00045","url":null,"abstract":"<p >This patent describes a novel class of novel indazole/azaindazole-substituted cyclopentapyrroles, which selectively inhibit the Leucine-Rich Repeat Kinase 2 (LRRK2) with G2019S mutation. These LRRK2 inhibitors are proposed for treating Parkinson’s diseases, Alzheimer’s disease, and other central nervous system (CNS) disorders.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 3","pages":"368–370 368–370"},"PeriodicalIF":3.5,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143600177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel Tryptamine Compounds as 5-HT2A Agonists for Treating Mood Disorders such as Depressive Disorders and Bipolar Disorders
IF 3.5 3区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2025-02-13 DOI: 10.1021/acsmedchemlett.5c0004710.1021/acsmedchemlett.5c00047
Ram W. Sabnis*,  and , Anika R. Sabnis, 

Provided herein are novel tryptamine compounds as 5-HT2A agonists, pharmaceutical compositions, use of such compounds in treating mood disorders such as depressive disorders and bipolar disorders and processes for preparing such compounds.

{"title":"Novel Tryptamine Compounds as 5-HT2A Agonists for Treating Mood Disorders such as Depressive Disorders and Bipolar Disorders","authors":"Ram W. Sabnis*,&nbsp; and ,&nbsp;Anika R. Sabnis,&nbsp;","doi":"10.1021/acsmedchemlett.5c0004710.1021/acsmedchemlett.5c00047","DOIUrl":"https://doi.org/10.1021/acsmedchemlett.5c00047https://doi.org/10.1021/acsmedchemlett.5c00047","url":null,"abstract":"<p >Provided herein are novel tryptamine compounds as 5-HT2A agonists, pharmaceutical compositions, use of such compounds in treating mood disorders such as depressive disorders and bipolar disorders and processes for preparing such compounds.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 3","pages":"373–374 373–374"},"PeriodicalIF":3.5,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143600242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of Indazole- and Azaindazole-Substituted Cyclopentapyrroles as G2019S Leucine-Rich Repeat Kinase 2 Inhibitors for the Treatment of CNS Disorders.
IF 3.5 3区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2025-02-13 eCollection Date: 2025-03-13 DOI: 10.1021/acsmedchemlett.5c00045
Siyan Feng, Steven H Liang

This patent describes a novel class of novel indazole/azaindazole-substituted cyclopentapyrroles, which selectively inhibit the Leucine-Rich Repeat Kinase 2 (LRRK2) with G2019S mutation. These LRRK2 inhibitors are proposed for treating Parkinson's diseases, Alzheimer's disease, and other central nervous system (CNS) disorders.

{"title":"Identification of Indazole- and Azaindazole-Substituted Cyclopentapyrroles as G2019S Leucine-Rich Repeat Kinase 2 Inhibitors for the Treatment of CNS Disorders.","authors":"Siyan Feng, Steven H Liang","doi":"10.1021/acsmedchemlett.5c00045","DOIUrl":"10.1021/acsmedchemlett.5c00045","url":null,"abstract":"<p><p>This patent describes a novel class of novel indazole/azaindazole-substituted cyclopentapyrroles, which selectively inhibit the Leucine-Rich Repeat Kinase 2 (LRRK2) with G2019S mutation. These LRRK2 inhibitors are proposed for treating Parkinson's diseases, Alzheimer's disease, and other central nervous system (CNS) disorders.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 3","pages":"368-370"},"PeriodicalIF":3.5,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912279/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143655517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Many Faces: The Global Landscape of Medicinal Chemistry.
IF 3.5 3区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2025-02-12 eCollection Date: 2025-03-13 DOI: 10.1021/acsmedchemlett.5c00041
Lori Ferrins, Ashley Adams, Anna Junker
{"title":"Many Faces: The Global Landscape of Medicinal Chemistry.","authors":"Lori Ferrins, Ashley Adams, Anna Junker","doi":"10.1021/acsmedchemlett.5c00041","DOIUrl":"10.1021/acsmedchemlett.5c00041","url":null,"abstract":"","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 3","pages":"348-350"},"PeriodicalIF":3.5,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912277/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143655521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Many Faces: The Global Landscape of Medicinal Chemistry
IF 3.5 3区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2025-02-12 DOI: 10.1021/acsmedchemlett.5c0004110.1021/acsmedchemlett.5c00041
Lori Ferrins*, Ashley Adams and Anna Junker*, 
{"title":"Many Faces: The Global Landscape of Medicinal Chemistry","authors":"Lori Ferrins*,&nbsp;Ashley Adams and Anna Junker*,&nbsp;","doi":"10.1021/acsmedchemlett.5c0004110.1021/acsmedchemlett.5c00041","DOIUrl":"https://doi.org/10.1021/acsmedchemlett.5c00041https://doi.org/10.1021/acsmedchemlett.5c00041","url":null,"abstract":"","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 3","pages":"348–350 348–350"},"PeriodicalIF":3.5,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143600239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
ACS Medicinal Chemistry Letters
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1